Drug firmBoehringer Ingelheim (India) on Wednesday said it has received approval from the Drugs Controller General of India(DCGI) for Nintedanib used for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults.
Following the United States Food and Drug Administration (USFDA)'s approval in September 2019, Nintedanib in SSc-ILD has so far been approved in 15 countries including the European Union, Canada, Japan and Brazil, Boehringer Ingelheim (India) said in a statement.
"Systemic sclerosis is a life-altering condition and Nintedanib is the first and only approved treatment for SSc-ILD, serving a high unmet need making a real positive difference. For the treatment of people living with SSc-ILD, this is a quantum leap," Boehringer Ingelheim India MDSharad Tyagi said.
The DCGI approval is a milestone in Boehringer Ingelheim's dedication towards providing the best possible treatment for people living with SSc-ILD in India, he added.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)